SPRYCEL (Dasatinib)- 50mg

SPRYCEL (Dasatinib) belongs to the signal transduction inhibitor category of targeted therapies.  It particularly interferes with multiple protein-tyrosine kinases.

SPRYCEL is used for;

• Treatment of chronic myelogenous leukemia (CML) with resistance or intolerance to prior therapy.
• Treatment of Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) with resistance or intolerance to prior therapy.